Stock Information & Shareholder Returns | Takeda Investor Relations

1. Views on Cost of Capital and Market Valuation

Takeda’s management constantly assesses the Company’s cost of capital, profitability and market valuation utilizing various metrics relevant to our business.

While Takeda’s management reviews profitability using both reported and non-IFRS metrics, Takeda’s profitability on a reported basis is significantly impacted by non-core / non-cash items, such as amortization of acquired intangible assets, as is the case with many other global pharmaceutical companies. Furthermore, profitability and valuation metrics can be significantly impacted by unforeseeable factors, both internal and in the external business environment, and therefore it is difficult to predict or set targets on these metrics. Therefore, Takeda does not provide detailed forecasts other than single-year management guidance and financial forecasts, and descriptive goals for mid-to-long term revenue and profitability.

Guided by our commitment to patients, our people, and the planet, Takeda management firmly believes that our focus on delivering growth - through investment in our product portfolio, R&D, and business development - alongside our commitment to competitive total shareholder returns, will result in the realization of competitive market valuation in the mid-to-long term.

2. Dividends Overview

3. Shareholder Returns and Dividends

Takeda has adopted a progressive dividend policy of increasing or maintaining the annual dividend per share each year. In addition, Takeda may engage in the acquisition of its own shares when appropriate, including to enhance capital efficiency and improve shareholder returns.

Takeda distributes dividends twice a year. In FY2024, Takeda intends to return cash to shareholders with an annual dividend of 196 yen per ordinary share, consisting of interim and fiscal year-end dividends of 98 yen per share.

Important Dates

Interim Dividends

Year End Dividend

For American Depositary Share (ADS) holders

Takeda American Depositary Shares (ADS) are listed on the NYSE.

Please note that 2 ADSs represent 1 ordinary share, and therefore the ADS dividend amount is ½ of the ordinary share amount. The final US Dollar dividend amount will only become known at the timing of payment when our ADS Depositary, the Bank of New York Mellon, exchanges the dividends from Japanese Yen to US Dollars for ADS holders. The final USD amount will be stated on the Bank of New York Mellon’s website.

Registered holders can reach out to Bank of New York Mellon’s transfer agent, CPU (Computershare) for additional information, whereas the beneficial ADS holders holding through their brokers should reach out to their respective brokers for more information. [email protected]

• In North America: 888-796-2480

• International: +1 201-680-6825

Registered holders can also reach out to CPU via the following:

Regular mail

BNY Mellon P.O. Box 43006 Providence RI 02940-3078 United States of America

Courier / overnight / certified / registered delivery

BNY Mellon 150 Royall Street - Suite 101 Canton, MA 02021 United States of America

Stock Index (As of December 31, 2024)

• Number of shareholders: 655,354

• Number of shares: 1,590,937,609

Principal Shareholders

For American Depositary Shares (ADS) Holders

ADS Depositary Bank: The Bank of New York Mellon (Computershare)

ADS Holders can contact The Bank of New York Mellon's transfer agent Computershare via telephone, in writing or email as follows:

Telephone 

• Toll Free Number within the United States: 1-888-796-2480

• Number for International Calls: +1-201-680-6825

Regular mail 

BNY Mellon P.O. Box 43006 Providence RI 02940-3078 United States of America

Courier / overnight / certified / registered delivery

BNY Mellon 150 Royall Street - Suite 101 Canton, MA 02021 United States of America

Email: [email protected] 

Website: http://www.adrbnymellon.com/

For Former Shire Shareholders (Ordinary Shares) who have not made an election in respect of the consideration 

Please contact Corporate Nominee Facility, EQUINITI, via telephone or in writing as follows:

Telephone (Shareholder Helpline) 

0330-123-5506 (+44-121-415-0856 if calling from outside the UK)

A text phone is also available on:

0371-384-2255 (+44-121-415-7028 if calling from outside the UK)  Lines open 8.30am to 5.30pm (UK time), Monday to Friday (excluding public holidays in England and Wales).

In writing 

The Manager, Equiniti Corporate Nominees Limited,  Aspect House, Spencer Road,  Lancing, West Sussex, BN99 6DA United Kingdom

Or you can send us your query securely by completing the online form at: help.shareview.co.uk

In accordance with the Scheme of Arrangement Corporate Nominee Facility will end two (2) years from the Scheme Effective Date (January 8, 2019). After such time, any remaining shares will be sold and a Sterling cheque issued.  Learn more

Find a list of frequently asked questions specific to Investor Relations, or reach out to us through contact information.